What is Artios Pharma?
Artios Pharma is at the forefront of developing innovative anti-cancer therapies by targeting DNA damage response (DDR) pathways. The company's strategy leverages the deep expertise of its team in DDR drug development to create differentiated pharmaceutical candidates. Its pipeline includes clinical-stage assets such as the ATR inhibitor alnodesertib and the DNA Polymerase theta (Pol) inhibitor ART6043, alongside pre-clinical programs like DDRi-ADCs. These candidates are engineered with novel biological approaches and pharmaceutical properties aimed at precisely eliminating cancer cell survival mechanisms, addressing the needs of patients with hard-to-treat cancers.
How much funding has Artios Pharma raised?
Artios Pharma has raised a total of $385.2M across 4 funding rounds:
Series A
$33.2M
Series B
$84M
Series C
$153M
Series D
$115M
Series A (2016): $33.2M with participation from Merck Ventures, AbbVie Ventures, SV Life Sciences, Arix Bioscience, and Imperial Innovations Group plc
Series B (2018): $84M, investors not publicly disclosed
Series C (2021): $153M supported by TCG X, Omega Funds, Invus, Piper Sandler, Sofinnova Partners, Avidity Partners, and Deep Track Capital
Series D (2025): $115M, investors not publicly disclosed
Key Investors in Artios Pharma
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, focused on investing in innovative technologies and products with the potential to significantly impact Merck's core business areas. They invest globally in transformational ideas and take an active role in their portfolio companies.
AbbVie Ventures
AbbVie Ventures is part of AbbVie, a company operating in the Research & Development industry, focusing on innovative therapies. They invest in companies that align with AbbVie's strategic interests in advancing healthcare solutions.
SV Life Sciences
SV Health Investors is a specialist investment firm dedicated to backing innovative health care and life science companies. They provide capital, sector expertise, and active support to help companies grow and create value.
What's next for Artios Pharma?
With its recent major strategic investment, Artios Pharma is poised to accelerate the development and potential commercialization of its promising oncology pipeline. The company's focus on exploiting DDR pathways positions it to create new classes of medicines. Future endeavors will likely involve advancing its clinical-stage candidates through further trials and expanding its pre-clinical programs, with the ultimate goal of improving outcomes for patients battling difficult-to-treat cancers. The substantial backing provides the necessary resources to pursue these ambitious objectives and solidify its position in the competitive oncology landscape.
See full Artios Pharma company page
